Vancouver, British Columbia – (July 16, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announced today that the Company has been granted a Full Registered Trademark Status from the US Patent and Trademark Office for its Company Brand Name “BioMark”. The term “BioMark” was selected by the company in reference to their Biomarker Testing capabilities in the fields of cancer treatment and anti-cancer preparations.
Biomarker testing is comprised of a group of tests that looks for specific molecular signs (or signatures) related to cancer so that doctors can plan the best cancer treatment care. In addition, the trademark can also be used for claiming preparation of anti-cancer properties.
“We believe that this trademark significantly enhances our brand while clearly communicating our mission and proficiency in leveraging novel biomarker testing methods for cancer treatment and development of anti-cancer preparation,” said Rashid Bux, Chief Executive Officer of BioMark Diagnostics Inc. “Going forward, this trademark will provide us with an additional layer of name recognition with investors, potential bio-technology partners and members of the scientific community. This is an opportune time to receive the trademark as we strive to accelerate commercialization of our assays and to establish ourselves as a market leader in the rapidly growing cancer medical testing, treatment and anti-cancer preparation sector.”
